Certara initiated with a Buy at Rothschild & Co Redburn

Rothschild & Co Redburn initiated coverage of Certara (CERT) with a Buy rating and $10 price target The firm views Certara as the leader in biosimulation, which it says can aid the discovery of potential drug targets and reduce the need for early stage clinical work. Certara needs to increase penetration into discovery and preclinical phases, and it acquisition of Chemaxon boosts its presence in these areas, the analyst tells investors in a research note.